BioCentury
ARTICLE | Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

March 26, 2020 1:22 AM UTC

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their COVID-19 countermeasures.

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) will collaborate with the Biomedical Advanced Research Development Authority, FDA and other U.S. public health agencies to generate a COVID-19 therapy derived from convalescent plasma collected from COVID-19 patients. The company will process the plasma into hyperimmune globulin and support preclinical and clinical studies evaluating the therapy’s efficacy...